Literature DB >> 10639640

Low-Molecular-Weight Heparin Should Replace Unfractionated Heparin for Treatment of Venous Thrombosis and Unstable Angina.

.   

Abstract

Entities:  

Year:  1997        PMID： 10639640     DOI： 10.1023/a:1008893231863

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  13 in total

Review 1.  Heparin.

Authors:  J Hirsh
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

2.  A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.

Authors: 
Journal:  Thromb Haemost       Date:  1991-03-04       Impact factor: 5.249

3.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.

Authors:  G Simonneau; B Charbonnier; H Decousus; B Planchon; J Ninet; P Sie; M Silsiguen; S Combe
Journal:  Arch Intern Med       Date:  1993-07-12

4.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

5.  Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.

Authors:  S Lopaciuk; A J Meissner; S Filipecki; K Zawilska; J Sowier; L Ciesielski; M Bielawiec; S Glowinski; E Czestochowska
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

6.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

7.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

8.  Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.

Authors: 
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321

9.  Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.

Authors:  P Lindmarker; M Holmström; S Granqvist; H Johnsson; D Lockner
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

10.  A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.

Authors:  G Bratt; E Törnebohm; S Granqvist; W Aberg; D Lockner
Journal:  Thromb Haemost       Date:  1985-12-17       Impact factor: 5.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.